Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kolbeinn Gudmundsson

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Laeknabladid|February 27, 2025
[Living with type 1 diabetes]Kolbeinn Gudmundsson
Diabetes|September 28, 2004
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapyJørn V Sagen, Helge Raeder, Eba Hathout, et al.
JAMA|May 12, 2005
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trialHakon Hakonarson, Sverrir Thorvaldsson, Anna Helgadottir, et al.
Nature Reviews. Drug Discovery|March 2, 2010
Challenges with advanced therapy medicinal products and how to meet them, , Christian K Schneider, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Laeknabladid|February 27, 2025
[Living with type 1 diabetes]Kolbeinn Gudmundsson
Diabetes|September 28, 2004
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapyJørn V Sagen, Helge Raeder, Eba Hathout, et al.
JAMA|May 12, 2005
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trialHakon Hakonarson, Sverrir Thorvaldsson, Anna Helgadottir, et al.
Nature Reviews. Drug Discovery|March 2, 2010
Challenges with advanced therapy medicinal products and how to meet them, , Christian K Schneider, et al.
Pageof 1